"ADDITIONAL VALUE" OF NASAL THERAPY IN STANDARD THERAPY FOR COVID-19 PATIENTS WITH OLFACTORY DISORDERS: A Preliminary Randomized Controlled Clinical Trial

UMIN ID: UMIN000045185

Registered date:18/08/2021

Basic Information

• Recruitment status: Complete: follow-up complete
• Health condition(s) or Problem(s) studied: olfactory disorder in COVID-19
• Date of first enrollment: 2020/08/01
• Target sample size: 24
• Countries of recruitment: Asia(except Japan)
• Study type: Interventional

Intervention(s)

COVID standar Therapy for 2 weeks
COVID standar Therapy and nasal treatment (mometasone nasal spray 2dd2 spray, normosaline nasal irrigation 2dd30 cc both nostrils, oxymethazolin 0,5% nasa spray 1dd2 spray before bedtime, aromatic vaporub 1dd1 on neck and chest before bedtime) for 2 weeks

Outcome(s)

• Primary Outcome: improvement of olfactory disorders both subjective (visual analog score) and objective by Alcohol sniff test and Intravenous olfaction test results after treatment

Key inclusion & exclusion criteria

• Age minimum: 18years-old
• Age maximum: 50years-old
• Gender: Male and Female
• Exclude criteria: 1. Cognitive and conciousness impairment 2. Severe dyspnea and unstable vital sign 3. History of olfactory and taste disturbance before COVID 4. History of chronic rhinosinusitis and severe head trauma 5. History of routine use of steroid intranasal, decongestan before COVID-19 6. History of skin and vascular problem

Related Information

• Primary Sponsor: there were no sponsors available
• Source(s) of Monetary Support: Rhinology division ORL-HNS Department Cipto Mangunkusumo General Hospital